Literature DB >> 8761303

Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells.

S Sakano1, R Serizawa, T Inada, A Iwama, A Itoh, C Kato, Y Shimizu, F Shinkai, R Shimizu, S Kondo, M Ohno, T Suda.   

Abstract

HTK is a receptor tyrosine kinase that belongs to the Eph subfamily. An extensive screening using BIAcore system revealed that a colon cancer cell line, C-1, expressed the ligand for HTK. From the conditioned medium of C-1 cells, a soluble form of ligand was purified by receptor affinity chromatography, and the isolation of full-length cDNA revealed that this ligand is identical to the human HTK ligand (HTKL) previously reported. HTK receptor tyrosine phosphorylation was induced by membrane-bound or clustered soluble HTKL but not by unclustered soluble HTKL, indicating that HTKL requires cell-to-cell interaction for receptor activation. Binding analysis demonstrated that HTKL binds to HTK with a much higher affinity (Kd: 1.23 nM) than the other transmembrane-type ligand for Eph family, LERK-2/ELKL (Kd: 135 nM). The expression of HTK in cord blood cells was upregulated after the culture in the presence of stem cell factor. Clustered soluble HTKL stimulated the proliferation of sorted HTK+ cord blood cells and a hematopoietic cell line, UT-7/EPO from which HTK was isolated. These findings suggest the involvement of HTK-HTKL system in the proliferation of HTK+ hematopoietic progenitor cells in the hematopoietic environment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761303

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling.

Authors:  Ombretta Salvucci; Maria de la Luz Sierra; Jose A Martina; Peter J McCormick; Giovanna Tosato
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

2.  The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.

Authors:  Nathalie Kertesz; Valery Krasnoperov; Ramachandra Reddy; Lucy Leshanski; S Ram Kumar; Sergey Zozulya; Parkash S Gill
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

3.  Mutations in EPHB4 cause human venous valve aplasia.

Authors:  Oliver Lyons; James Walker; Christopher Seet; Mohammed Ikram; Adam Kuchta; Andrew Arnold; Magda Hernández-Vásquez; Maike Frye; Gema Vizcay-Barrena; Roland A Fleck; Ashish S Patel; Soundrie Padayachee; Peter Mortimer; Steve Jeffery; Siren Berland; Sahar Mansour; Pia Ostergaard; Taija Makinen; Bijan Modarai; Prakash Saha; Alberto Smith
Journal:  JCI Insight       Date:  2021-09-22

4.  Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes.

Authors:  Steeve Kwan Tat; Jean-Pierre Pelletier; Nathalie Amiable; Christelle Boileau; Martin Lavigne; Johanne Martel-Pelletier
Journal:  Arthritis Res Ther       Date:  2009-08-07       Impact factor: 5.156

5.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Authors:  Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

6.  A new ephrin-A1 isoform (ephrin-A1b) with altered receptor binding properties abrogates the cleavage of ephrin-A1a.

Authors:  Eivind F Finne; Else Munthe; Hans-Christian Aasheim
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

7.  EphA4 has distinct functionality from EphA7 in the corticothalamic system during mouse brain development.

Authors:  Alexander I Son; Kazue Hashimoto-Torii; Pasko Rakic; Pat Levitt; Masaaki Torii
Journal:  J Comp Neurol       Date:  2015-12-03       Impact factor: 3.215

Review 8.  EphrinB2-EphB4-RASA1 Signaling in Human Cerebrovascular Development and Disease.

Authors:  Xue Zeng; Ava Hunt; Sheng Chih Jin; Daniel Duran; Jonathan Gaillard; Kristopher T Kahle
Journal:  Trends Mol Med       Date:  2019-02-25       Impact factor: 11.951

9.  Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.

Authors:  Yen-Ching Lee; Janeanne R Perren; Evelyn L Douglas; Michael P Raynor; Maria A Bartley; Peter G Bardy; Sally-Anne Stephenson
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

10.  The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells.

Authors:  F N Karanu; B Murdoch; L Gallacher; D M Wu; M Koremoto; S Sakano; M Bhatia
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.